Reducing Drug Prices—The Most Favored Nation Policy vs Price Negotiation

This Viewpoint discusses the most favored nation policy vs price negotiation for reducing drug prices.

Corresponding Author: Amar H. Kelkar, MD, MPH, Division of Transplantation and Cellular Therapy, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (amarh_kelkar@dfci.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.